מסלולי האיתות של GPCR (GPR84) בעל חישה לחומצות שומן שומרים על הומאוסטזיס הסחוס ומגנים מפני דלקת מפרקים ניוונית (OA)
GLP-1 משפר את פעילות הגליוקסלאז ברקמות השומן ואת היווצרות הקפילרות ובכך משפר את הרגישות לאינסולין בסוכרת מסוג 2
CCB, Local Anesthetic. Lidocaine HCl 1.5%, Nifedipine 0.3%. RECTAL CR.: 30g. Should be applied twice dly. for at least 3 wks. See lit.
Tmt. of anal fissures and proctolog. general. associate. with anal sphincter hypertonia.
C/I: Hypersens. to the active ingred., partic. to Lidocaine (& other local anesthet. with a similar amidic type structure). Presumed or ascertained preg. & lact.
Analgesic, Antipyretic, Opioid. Caffeine 50 mg, Codeine Phosphate 15 mg, Paracetamol 500 mg. CAPLETS: 12, 24. 1 capl. × 3-4 times/day. For severe pains - 2 capl. 3-4 times/day. Do not exceed a dosage of 8 capl. in 24 hrs. See lit.
For the relief of pain and coughs and for the reduction of fever accompanied by pain.
C/I: Hypersens. 1st & 3rd trim. of preg. Lact. Child. under 12 yrs. old. Adolesc. over 12 yrs. old and under 18 yrs. old after surg. remov. of their tonsils or adenoids. Concom. use with medic. contain. paracetamol /codeine. Pts. with respirat. depress. Pts. who are known as ultra-rapid metabolizer.
Urinary Tract Analgesic. Phenazopyridine (as HCl) 100 mg. TABS: 30. Adult and children over 12
years: 2 drugs. 3 x dly. Aft. meals.
Children from 6 to 12 years: 12mg/kg
bdy wt divided into 3 daily doses.
Relief pain, burning, urgency.
C/I: G6PD deficiency, renal insuffic.
hepatic insuffic., hepatitis, hypersens.
Antibacterial, Antifungal, Corticosteroid. Gramicidin 0.25 mg/g, Neomycin Sulphate 2.5 mg/g, Nystatin 100000 IU/g, Triamcinolone 1 mg/g. CREAM: 5, 15 g. Apply 2-3 x dly.
Allerg. and infect. dermatit., eczema,
cutan. candidiasis, anogenital prurit.
C/I: T.B., herpes simplex, vaccinia,
varicella, lesions not suscept. to nystatin.
Corticosteroid. Triamcinolone Acetonide 0.055% W/W. NASAL SPRAY (metered dose pump):
120 x 55 μg/spray. Adults, child >12 yrs: 2
sprays in ea. nostril 1x dly. Titr. individ. to
min. effect. dose. When sympts. controlled, may reduce to 1 spray/nostril. Child 6-12 yrs: 1 spray in ea. nostril 1 x dly, may incr. to 2 sprays in severe sympts. Maintain. on lowest effect. dose. Child 2-5 yrs: 1 spray in ea. nostril 1x dly.
Seas. and peren. allerg. rhinit.
C/I: Hypersens. Candida alb.infec.
child under 2 yrs. not recom
Stabilizer of transthyretin.. Tafamidis 61 mg. SOFT. CAPS.: 3×10. 61 mg (one cap.) orally once dly, swallow. whole and not crushed or cut., with/ without food.
Vyndamax and Vyndaqel (tafamidis meglumine) are not substitutab.on a per mg basis. Ped. use.: not indic. for child., adolesc. under 18 yrs. old. Geriat. use: No dosage adjust.is require.for elderly pts. (≥65 years).
Tmt. of the cardiomyopat. of wild type or heredit. transthyretin-mediated amyloidosis (ATTR-CM) in adult.to reduce cardiovasc. mortal. and cardiovasc.-related hospitalization.
Monoclonal Antibody. Bevacizumab 25 mg/ml. VIAL (Concent. for sol. for infus.):1×4 (100 mg),16 ml (400mg).
Dosage must be ajust. indivd. accord. to indicat. and pt. med. condit.
Tmt. of adult pts. with Metast.carcinoma of the colon or rectum: in comb.with fluoropyrimidine-based chemother.
1ST -line tmt. of adult pts. with metastat. breast cancer: in comb. with paclitaxel. For further informat., as to human epiderm. growth factor receptor 2 (HER2) status see lit.
1ST -line tmt. of adult pts. with unresectable advance., metastat. or recur. non-small cell lung cancer other than predominant. squamous cell histology in addition to platinum-based chemother.
1st -line tmt. of adult pts. with unresect. advanced, metastat. or recur. non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activat. mutations in comb. with erlotinib.
1ST -line tmt. of adult pts. with advance. and/or metastat. renal cell cancer: in comb. with interferon alfa-2a.
Tmt. of glioblastoma in pts. with progress. dis. follow. prior ther. as a single agent.
Front-line tmt. of advanced (FIGO stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer in pts. who are at high risk for recurrence (residual dis. after debulking): in comb. with carboplatin & paclitaxel. Tmt. of adult pts. with first recurrence of platinum-sensit. epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior ther. with bevacizumab or other VEGF inhib. or VEGF receptor-targeted agents: in comb. with carboplatin and gemcitabine, is indicat. for MVASI in comb. with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the tmt. of adult pts. with platinum-resist. recur. epithelial ovarian, fallopian tube, or prim. peritoneal cancer who received no more than two prior chemother. regimens and who have not received prior ther. with bevacizumab or other VEGF inhib. or VEGF receptor-targeted agents.
Tmt. of adult pts. with persist., recur.,or metastat. carcinoma of the cervix, in pts. who cannot receive platinum ther. in comb.with paclitaxel &cisplatin or, paclitaxel & topotecan.
Hypersens. to Chinese Hamster Ovary (CHO) cell products or other recomb.human or humanized antibod.
Antifungal. Anidulafungin 100mg. VIAL:1. A single 200 mg load. dose should be admin. on Day 1, follow. by 100 mg dly. thereafter. Durati.of tmt. should be based on the pt’s. clinic. response. In general, antifung. ther. should cont. for at least 14 d. after the last positi. culture.
Durat. of tmt. There are insuffic. data to support the 100 mg dose for longer than 35 d. of tmt.
For IV use only, must not be admin. as a bolus inj. See lit.
Tmt. of invas. candidiasis in adult Indications pts.
Hypersens. to other meds. products of the echinocandin class.
Topisomerase 1 inhibitor. Irinotecan HCl Trihydrate 20mg/ml. GLASS VIAL (Concent. for sol. for infus.):1× 5, 15, 25ml
Dosage must be ajust. individ.
For the tmt. of pts. with metast. colorec. cancer: In comb. with 5-fluorouracil and folinic acid in pts. without prior chemother. for metastat. dis. As a single agent in pts. who have failed an established 5-fluorouracil contain. tmt. regimen.
For tmt. of pts. with small cell lung cancer.
For the tmt. of pts. with gastr. cancer.
Irinotecan in comb. with leucovorin,
Oxaliplatin and 5-fluorouracil, for the 1st -line tmt. of pts. with metastat. pancreat. adenocarcinoma. metastat. pancreat. adenocarcinoma.
Cation exchange polymer. Patiromer (as patiromer sorbitex calcium) 8.4, 16.8 gr. SACHET.( Pwdr. for oral susp.):30.
The recom. starting dose is 8.4 g ×1/d.
The dly. dose may be adjust. in intervals of 1 wk. or longer, based on the serum K+ level and the desired target range. The dly. dose may be incr. or decreas. by 8.4 g as necessary to reach the desired target range, up to a max. dose of 25.2 g dly. If serum K+ falls below the desired range, the dose should be reduced or discount.
Miss. dose should be taken as soon as possible on the same day. The miss. dose should not be taken with the next dose. Admin. should be separated by 3 hrs. from other oral meds.
The onset of action occurs 4-7 hrs. after admin. It should not replace emerg. tmt. for life-threaten. hyperkalaemia. See lit. Tmt. of hyperkalaemia in adults.